Global biopharmaceutical company Starpharma, announced on Friday it has signed a sales and distribution agreement for its Viraleze antiviral nasal spray with Admenta Italia Group, a leading pharmaceutical retail and wholesale distribution company in Italy.
The Italian OTC pharmaceutical market is the third-largest in Europe after Germany and the UK.
Admenta operates over 260 pharmacies under its LloydsFarmacia brand, including 13 parapharmacies and 50 franchising Pharmacies in Italy, as well as supplying over 2,500 other pharmacies, parapharmacies, drugstores and hospitals.
Viraleze is expected to be available to Italian consumers in stores and via LloydsFarmacia’s online platform this quarter. Under the agreement, Starpharma will supply Viraleze, with Admenta responsible for the distribution, sales, and marketing of the product in Italy.
Viraleze is a broad-spectrum antiviral nasal spray, applied in the nose to provide a physical barrier - between viruses and the nasal mucous membrane - that traps and irreversibly inactivates virus, including SARS-CoV-2. The antiviral agent in Viraleze has been shown in laboratory studies to have potent antiviral and virucidal activity in multiple respiratory viruses and multiple variants of SARS-CoV-2, including inactivation of >99.9% of the highly infectious Delta variant.
Viraleze is currently registered in Europe and India, and is available in certain markets online. In the UK Viraleze is partnered with LloydsPharmacy, and Starpharma is in advanced discussions with other potential commercial partners elsewhere in Europe, India, Asia and other regions. Viraleze is not registered for sale or supply in Australia.
Dr Jackie Fairley, CEO of Starpharma commented: “We are very pleased to have partnered with Admenta in Italy and we look forward to having Viraleze available soon to Italian consumers, through pharmacies as well as through the leading LloydsFarmacia online platform.”